These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849 [TBL] [Abstract][Full Text] [Related]
9. [Status of Langerhans cell histiocytosis in children and adults]. Kudo K Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease]. Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230 [No Abstract] [Full Text] [Related]
11. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z; Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769 [TBL] [Abstract][Full Text] [Related]
12. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis. Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280 [TBL] [Abstract][Full Text] [Related]
13. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease. Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With Subbiah V; Gervais R; Riely G; Hollebecque A; Blay JY; Felip E; Schuler M; Gonçalves A; Italiano A; Keedy V; Chau I; Puzanov I; Raje NS; Meric-Bernstam F; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM JCO Precis Oncol; 2019; 3():. PubMed ID: 32914022 [TBL] [Abstract][Full Text] [Related]
15. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190 [TBL] [Abstract][Full Text] [Related]
16. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease. Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516 [TBL] [Abstract][Full Text] [Related]
17. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272 [TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in non-small-cell lung cancer patients with BRAF Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346 [TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
20. Hypoalphalipoproteinemia and BRAF Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]